tert-Butyl 4-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate

Catalog No. :
ACSKAF204
CAS No. :
2158298-66-7
Molecular Formula :
C23H30ClN5O2
Molecular Weight :
443.98

IUPAC Name:tert-butyl 4-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate

tert-Butyl 4-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate
Molecular FormulaC23H30ClN5O2
Molecular Weight443.98
SMILESO=C(N1CCN(C2=C3C(CN(CC4=CC=CC=C4)CC3)=NC(Cl)=N2)CC1)OC(C)(C)C
InChI KeyATCVJBOYOXQANF-UHFFFAOYSA-N
Synonym1-Piperazinecarboxylic acid, 4-[2-chloro-5,6,7,8-tetrahydro-7-(phenylmethyl)pyrido[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester;tert-Butyl 4-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate
CAS No.2158298-66-7

Synthetic Route by SureRoute

1. ACSKAF204 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACYJAU589 route compound structure diagram
    ACYJAU5891059735-34-0 In Stock
  4. Then
  5. ACSKAF204 route product structure diagram
    ACSKAF2042158298-66-7
Inquiry

2. ACSKAF204 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSKAF204 route product structure diagram
    ACSKAF2042158298-66-7
Inquiry

Comments (0)